Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.40
Bid: 1.30
Ask: 1.50
Change: 0.00 (0.00%)
Spread: 0.20 (15.385%)
Open: 1.45
High: 1.45
Low: 1.40
Prev. Close: 1.40
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IMAGING BIOMETRICS ANNOUNCES PARTNERSHIP

11 Apr 2018 07:00

RNS Number : 4904K
Flying Brands Limited
11 April 2018
 

 

 

FLYING BRANDS' SUBSIDIARY IMAGING BIOMETRICS ANNOUNCES DISTRIBUTION PARTNERSHIP WITH AI EXCHANGE PLATFORM, ENVOY AI

 

IB Neuro and IB Delta T1 Maps are now available on EnvoyAI's artificial intelligence Exchange

 

 

Flying Brand's newly acquired subsidiary Imaging Biometrics®, LLC ("IB"), a medical imaging software company specialising in advanced visualisation and analytics, has entered into a distribution agreement with EnvoyAI, a leading artificial intelligence ("AI") Exchange platform. IB Neuro, the premier magnetic resonance ("MR") imaging dynamic susceptibility contrast (DSC) perfusion solution, and IB's Delta T1 mapping algorithm, are now available for purchase on the EnvoyAI Exchange.

 

Dr. Steven Rothenberg, Chief Medical Officer at EnvoyAI said, "We recently added Imaging Biometrics' FDA cleared post-processing solutions to the EnvoyAI Exchange. The proprietary quantitative and automated algorithms contained in IB Neuro and IB Delta Suite provide clinicians with incredible value by producing unique imaging biomarkers that enable them to accurately monitor treatment response in brain tumor patients."

 

"This partnership with EnvoyAI enables immediate and widespread access to our proven and quantitative imaging biomarkers for neuro radiologists, neuro-oncologist, and neuro surgeons," said Michael Schmainda, CEO of IB. "The need to accurately quantify changes in brain tumor patients is becoming more important and yet increasingly difficult due to the challenging side effects of newer therapies and cancer fighting agents. The exclusive technology contained in IB's products overcome these difficulties and, through the unique additional information made available, aid the treatment team's ability to rapidly and objectively assess whether patients are responding to treatment. We are delighted to participate on the EnvoyAI Exchange and look forward to providing sophisticated imaging solutions to benefit clinicians and their patients."

 

About EnvoyAI (www.envoyai.com)

EnvoyAI facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. EnvoyAI provides a developer platform, integrations, and an open API for algorithm developers, technology partners, and end users. EnvoyAI assists research institutions and emerging AI companies in the translation and commercialisation processes, starting with rapid deployment via a scalable, secure, cloud-based infrastructure with the ability to add local components to facilitate on-site deployments as well. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians.

About Imaging Biometrics® LLCImaging Biometrics develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

 

About Flying Brands PLC

Flying Brands PLC (Ticker:FBDU) is the parent company of StoneChecker® and Imaging Biometrics® focused on advanced and state of the art medical software and services. (www.flyingbrands.co.uk).

The Directors of Flying Brands Limited accept responsibility for the contents of this announcement.

 

 **ENDS**

 

For further information please contact:

 

Flying Brands Limited

Qu Li/Trevor Brown/Vinod Kaushal

Tel: 020 7469 0930

 

 

Peterhouse Corporate Finance (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRKMGMDVGGGRZM
Date   Source Headline
16th Jul 20187:00 amRNSPlacing, Notice of AGM and GM
2nd Jul 20188:34 amRNSMedimsight and IB Enter into Partnership
13th Jun 20187:00 amRNSImaging Biometrics and QMENTA announce partnership
9th May 20187:00 amRNSIB Software Chosen by St. Savvas Oncology Hospital
30th Apr 20184:25 pmRNSFinal Results
11th Apr 20187:00 amRNSIMAGING BIOMETRICS ANNOUNCES PARTNERSHIP
29th Mar 20182:52 pmRNSTotal Voting Rights
13th Mar 201810:54 amRNSTotal Voting Rights
13th Mar 20187:40 amRNSAcquisition of Imaging Biometrics
6th Mar 20187:00 amRNSStoneChecker signs agreement with Korea ISG
8th Feb 20181:44 pmRNSPotential Acquisition
8th Feb 20189:05 amRNSSecond Price Monitoring Extn
8th Feb 20189:00 amRNSPrice Monitoring Extension
11th Dec 20177:00 amRNSCE marked release of StoneChecker® Software
6th Nov 20174:40 pmRNSSecond Price Monitoring Extn
6th Nov 20174:35 pmRNSPrice Monitoring Extension
26th Oct 20177:00 amRNSUpdate on Business Operations
9th Oct 20172:33 pmRNSHolding(s) in Company
18th Sep 20177:00 amRNSUpdate on Product Development and Warrant Exercise
4th Sep 20179:49 amRNSStone Checker Update
30th Aug 201710:04 amRNSHolding(s) in Company
17th Aug 20177:01 amRNSDirector Dealings
17th Aug 20177:00 amRNSHalf-year Report
14th Aug 201710:12 amRNSHolding(s) in Company
27th Jul 20174:40 pmRNSSecond Price Monitoring Extn
27th Jul 20174:35 pmRNSPrice Monitoring Extension
11th Jul 20177:00 amRNSUpdate on Operations
3rd Jul 20177:00 amRNSConversion of Convertible Loan Notes into Equity
27th Jun 20174:40 pmRNSSecond Price Monitoring Extn
27th Jun 20174:35 pmRNSPrice Monitoring Extension
16th Jun 20177:00 amRNSReadmission to the London Stock Exchange
15th Jun 20171:42 pmRNSResult of Annual General Meeting & General Meeting
19th May 20177:00 amRNSProspectus, Placing & Expected Readmission
28th Apr 20173:12 pmRNSFinal Results
27th Feb 201711:51 amRNSHolding(s) in Company
20th Jan 20171:30 pmRNSAppointment of Non-Executive Director
26th Aug 201612:06 pmRNSHalf-year Report
30th Jun 201612:58 pmRNSProposed Acquisition and Suspension of Listing
31st May 20161:33 pmRNSHolding(s) in Company
27th May 201611:39 amRNSResult of AGM
5th May 20164:15 pmRNSHolding(s) in Company
4th May 20167:00 amRNSNotice of AGM
20th Apr 20167:00 amRNSHolding(s) in Company
20th Apr 20167:00 amRNSFinal Results
5th Apr 201610:48 amRNSStatement re Update
20th Nov 20157:00 amRNSBoard changes, corporate update, issue of CLN
21st Oct 20157:00 amRNSAppointment of Financial Adviser and Broker
25th Aug 20153:29 pmRNSHalf Yearly Report
16th Jul 201511:17 amRNSHolding(s) in Company
16th Jul 201511:15 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.